# Mark T. Lupa

> Mark T. Lupa is a Series A investor at High Country Venture backing Medical and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [High Country Venture](https://shizune.co/investors/profile/high-country-venture)
- Location: Boulder, United States
- Total investments: 6
- Last investment: Dec 2015
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/mark-t-lupa-302a828

Mark T. Lupa is a Series A investor at High Country Venture in Boulder focused on Medical and Biotechnology. Lupa holds a Bachelor’s of Science degree from Northwestern University, a Master’s degree from the University of Sussex (England) in Biomedical Engineering and completed his doctoral program in Pharmacology from the University of Lund, Sweden. He conducted neuroscience research for 15 years at institutions worldwide, including the University ofColorado and the University of California San Francisco.Dr. Lupa’s business experience came first in the brewing industry as founder, CEO and CFO of Tabernash Brewing Company, which was formed in 1993 and merged with Left Hand Brewing in 1998. Dr. Lupa then moved to the private investment company Tango to focus on technology and Life Science investments.He is currently Managing Director of High Country Venture, a venture capital fund in Boulder, Colorado, and has served as founding member of the Board of Directors of Taligen Therapeutics, Sierra Neuropharma, Oberon, DCS Surgical, and Theratogs.Dr. Lupa also served as CFO of Taligen from inception of the company in 2004 until early 2008.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Biotechnology | 2 | 33% |
| Hardware | 1 | 17% |
| Health Care | 1 | 17% |
| Developer Platform | 1 | 17% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series B | 2 | 33% |
| Series C | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TriSalus Life Sciences | Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $15M | Series C | Dec 02, 2015 |  |
| TriSalus Life Sciences | Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $18.2M | Series B | Nov 07, 2013 |  |
| TriSalus Life Sciences | Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $6.1M | Series A | Nov 08, 2011 |  |
| Taligen Therapeutics | Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factorsin the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. | $10M | Series B | Aug 23, 2010 |  |
| Taligen Therapeutics | Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factorsin the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. | $65M | Series B | Jan 01, 2008 |  |
| Taligen Therapeutics | Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factorsin the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. | $3.8M | Series A | Aug 01, 2005 |  |

6 of 6 investments shown.

## Co-investors
- [Partisan Management Group](https://shizune.co/investors/profile/partisan-management-group) — VC Fund, 3 deals together
- [MCG Capital](https://shizune.co/investors/profile/mcg-capital) — VC Fund, 2 deals together
- [KMG Capital Partners](https://shizune.co/investors/profile/kmg-capital-partners) — VC Fund, 1 deal together
- [Sanderling Ventures](https://shizune.co/investors/profile/sanderling-ventures) — VC Fund, 1 deal together
- [Tullis Health Investors](https://shizune.co/investors/profile/tullis-health-investors) — VC Fund, 1 deal together

## About High Country Venture

VC Fund · Boulder, United States

The Colorado Fund is a venture capital fund seeking to invest in seed and early stage businesses in Colorado. The fund will focus its investments in Life Sciences (including biotechnology, clean technology, and medical devices), information technology (including software and Internet companies) and retail. They encourage all qualified businesses inrural areas who are seeking capital to submit a business plan, regardless of the industry you are in.

4 contacts available at High Country Venture.

| Name | Title | Profile |
| --- | --- | --- |
| Christopher A. Marks | Team Member | https://shizune.co/investors/profile/christopher-a-marks |
| Mark T. Lupa | Managing Partner | https://shizune.co/investors/profile/mark-t-lupa |
| Rob Schmiedeler | partner | https://shizune.co/investors/profile/rob-schmiedeler |
| Scott Beck | Founder & CEO | https://shizune.co/investors/profile/scott-beck-1de8 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Mark T. Lupa invest in?

Mark T. Lupa invests primarily in Medical, Biotechnology and Hardware startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Mark T. Lupa last invest?

The most recent investment recorded for Mark T. Lupa closed in Dec 2015. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co